The advent of immune checkpoint inhibitors (ICIs)—antibodies that target either programmed cell death-1 (PD-1), its ligand (PD-L1), or the cytotoxic T-lymphocyte-associated antigen (CTLA-4)—transformed the treatment landscape for advanced/metastatic ccRCC [36,37]. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.